

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review	11
4. Data for the <i>Monographs</i>	11
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION.....	14
1. Exposure data	15
2. Studies of cancer in humans	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References	31
GENERAL REMARKS	33
ANTHRAQUINONE	41
1. Exposure Data	41
1.1 Chemical and physical data	41
1.2 Production and use.....	41
1.3 Occurrence and exposure	42
1.4 Regulations and guidelines	51
2. Cancer in Humans.....	51
2.1 Cohort and nested case-control studies	51
3. Cancer in Experimental Animals	57
3.1 Oral administration.....	57
4. Other Relevant Data	61

4.1 Absorption, distribution, metabolism, and excretion.....	61
4.2 Genetic and related effects.....	62
4.3 Mechanistic considerations.....	63
5. Summary of Data Reported.....	64
6. Evaluation.....	65
References.....	66
1-AMINO-2,4-DIBROMOANTHRAQUINONE.....	71
1. Exposure Data.....	71
1.1 Chemical and physical data.....	71
1.2 Production and use.....	72
1.3 Occurrence.....	72
1.4 Regulations and guidelines.....	72
2. Cancer in Humans.....	72
3. Cancer in Experimental Animals.....	73
3.1 Oral administration.....	73
4. Other Relevant Data.....	82
4.1 Absorption, distribution, metabolism, and excretion.....	82
4.2 Genetic and related effects.....	83
4.3 Other mechanistic considerations.....	85
5. Summary of Data Reported.....	86
6. Evaluation.....	86
References.....	87
2-NITROTOLUENE.....	89
1. Exposure Data.....	89
1.1 Chemical and physical data.....	89
1.2 Production and use.....	90
1.3 Occurrence.....	91
1.4 Regulations and guidelines.....	98
2. Cancer in Humans.....	99
2.1 Cohort studies.....	99
3. Cancer in Experimental Animals.....	100
3.1 Oral administration.....	100
4. Other Relevant Data.....	104
4.1 Absorption, distribution, metabolism and excretion.....	104
4.2 Genetic and related effects.....	106
4.3 Other mechanistic considerations.....	108
4.4 Susceptibility.....	109
4.5 Mechanisms of carcinogenesis.....	109
5. Summary of Data Reported.....	110
6. Evaluation.....	111
References.....	112

DIETHANOLAMINE	117
1. Exposure Data	117
1.1 Chemical and physical data	117
1.2 Production and use	118
1.3 Occurrence and exposure	120
1.4 Regulations and guidelines	122
2. Cancer in Humans	123
3. Cancer in Experimental Animals	126
3.1 Skin application	126
3.2 Genetically modified mouse	128
4. Other Relevant Data	128
4.1 Absorption, distribution, metabolism and excretion	128
4.2 Toxic effects	130
4.3 Genetic and related effects	130
4.4 Mechanistic data	131
4.5 Mechanisms of carcinogenesis	132
5. Summary of Data Reported	135
6. Evaluation	136
References	136
COCONUT OIL DIETHANOLAMINE CONDENSATE	141
1. Exposure Data	141
1.1 Chemical and physical data	141
1.2 Production and use	142
1.3 Occurrence	143
1.4 Regulations and guidelines	144
2. Cancer in Humans	144
3. Cancer in Experimental Animals	144
3.1 Skin application	144
4. Other Relevant Data	145
4.1 Absorption, distribution, metabolism, excretion	145
4.2 Genetic and related effects	146
4.3 Mechanisms of carcinogenesis	146
5. Summary of Data Reported	146
6. Evaluation	147
References	147
DI(2-ETHYLHEXYL) PHTHALATE	149
1. Exposure Data	149
1.1 Chemical and physical data	149
1.2 Production and use	150
1.3 Occurrence	152
1.4 Regulations and guidelines	174
2. Cancer in Humans	176
2.1 Studies specific for exposure to DEHP	176
2.2 Occupational exposure to phthalate plasticizers	177

3. Cancer in Experimental Animals	185
3.1 Inhalation	185
3.2 Oral administration	185
3.3 Intraperitoneal injection	190
3.4 Genetically modified mouse	190
3.5 Co-exposure with modifying agents	191
4. Other Relevant Data	192
4.1 Absorption, distribution, metabolism and excretion	192
4.2 Genetic and related effects	199
4.3 Mechanistic data	214
4.4 Susceptibility	251
4.5 Mechanistic considerations	253
5. Summary of Data Reported	257
6. Evaluation	260
References	260
BENZOPHENONE	285
1. Exposure Data	285
1.1 Chemical and physical data	285
1.2 Production and use	286
1.3 Occurrence	286
1.4 Regulations and guidelines	292
2. Cancer in Humans	293
3. Cancer in Experimental Animals	293
3.1 Oral administration	293
3.2 Dermal application	296
4. Other Relevant Data	296
4.1 Absorption and metabolism	296
4.2 Genetic and related effects	297
4.3 Toxic effects	297
4.4 Endocrine-disrupting effects	298
4.5 Mechanisms of carcinogenesis	299
5. Summary of Data Reported	300
6. Evaluation	301
References	301
METHYL ISOBUTYL KETONE	305
1. Exposure Data	305
1.1 Chemical and physical data	305
1.2 Production and use	306
1.3 Occurrence and exposure	306
1.4 Regulations and guidelines	309
2. Studies in Humans	309
3. Cancer in Experimental Animals	309
3.1 Inhalation	309
4. Other Relevant Data	312

4.1 Absorption, distribution, metabolism and excretion	312
4.2 Genetic and related effects.....	314
4.3 Toxic effects	314
4.4 Mechanistic considerations	316
5. Summary of Data Reported.....	319
6. Evaluation	321
References	321
CUMENE	325
1. Exposure Data	325
1.1 Chemical and physical data	325
1.2 Production and use.....	326
1.3 Occurrence	326
1.4 Human exposure	331
1.5 Regulations and guidelines	338
2. Cancer in Humans.....	338
3. Cancer in Experimental Animals	338
3.1 Inhalation exposure	338
3.2 Carcinogenicity of metabolites	343
4. Other Relevant Data	343
4.1 Absorption, distribution, metabolism and excretion	343
4.2 Genetic and related effects.....	344
4.3 Mechanistic data.....	345
4.4 Mechanisms of carcinogenesis	346
5. Summary of Data Reported.....	346
6. Evaluation	347
References	347
3-MONOCHLORO-1,2-PROPANEDIOL.....	349
1. Exposure Data	349
1.1 Chemical and physical data	349
1.2 Production and use.....	354
1.3 Occurrence	355
1.4 Regulations and guidelines	358
2. Cancer in Humans.....	359
3. Studies in Experimental Animals.....	359
3.1 Oral administration.....	359
3.2 Subcutaneous administration	362
3.3 Dermal application	362
4. Other Relevant Data	362
4.1 Absorption, distribution, metabolism and excretion	362
4.2 Genetic and related effects.....	363
4.3 Mechanistic considerations	363
4.4 Mechanisms of carcinogenesis	367
5. Summary of Data Reported.....	368
6. Evaluation	369
References	369

1,3-DICHLORO-2-PROPANOL	375
1. Exposure Data	375
1.1 Chemical and physical data	375
1.2 Production and use.....	376
1.3 Occurrence	378
1.4 Regulations and guidelines	379
2. Cancer in Humans.....	379
3. Cancer in Experimental Animals	379
3.1 Oral administration	379
4. Other Relevant Data	381
4.1 Absorption, distribution, metabolism, and excretion.....	381
4.2 Genetic and related effects.....	384
4.3 Mechanistic data.....	384
4.4 Mechanisms of carcinogenesis	386
5. Summary of Data Reported.....	386
6. Evaluation	387
References	387
2,4-HEXADIENAL	391
1. Exposure Data	391
1.1 Chemical and physical data	391
1.2 Production and use.....	392
1.3 Occurrence	392
1.4 Regulations and guidelines	396
2. Cancer in Humans.....	396
3. Cancer in Experimental Animals	396
3.1 Oral administration.....	396
4. Other Relevant Data	399
4.1 Absorption, distribution, metabolism, and excretion.....	399
4.2 Genetic and related effects.....	399
4.3 Mechanistic data.....	400
4.4 Mechanisms of carcinogenesis	401
5. Summary of Data Reported.....	401
6. Evaluation	402
References	402
METHYLEUGENOL	407
1. Exposure Data	407
1.1 Chemical and physical data	407
1.2 Production and use.....	408
1.3 Occurrence	409
1.4 Regulations and guidelines	416
2. Cancer in Humans.....	417
3. Cancer in Experimental Animals	417
3.1 Oral administration	417
3.2 Intraperitoneal injection	421
3.3 Carcinogenicity of metabolites	423

4. Other Relevant Data	423
4.1 Absorption, distribution, metabolism and excretion	423
4.2 Genetic and related effects.....	424
4.3 Mechanistic data.....	426
4.4 Susceptibility.....	427
4.5 Mechanisms of carcinogenesis	427
5. Summary of Data Reported.....	427
6. Evaluation	428
References	429
2-METHYLIMIDAZOLE.....	435
1. Exposure Data	435
1.1 Chemical and physical data	435
1.2 Production and use.....	436
1.3 Occurrence	436
1.4 Regulations and guidelines	437
2. Cancer in Humans.....	437
3. Cancer in Experimental Animals	437
3.1 Oral administration	437
4. Other Relevant Data	440
4.1 Absorption, distribution, metabolism and excretion	440
4.2 Genetic and related effects.....	441
4.3 Mechanistic data.....	442
4.4 Mechanisms of carcinogenesis	442
5. Summary of Data Reported.....	443
6. Evaluation	444
References	444
4-METHYLIMIDAZOLE.....	447
1. Exposure Data	447
1.1 Chemical and physical data	447
1.2 Production and use.....	447
1.3 Occurrence	448
1.4 Regulations and guidelines	452
2. Cancer in Humans.....	452
3. Cancer in Experimental Animals	452
3.1 Oral administration	452
4. Other Relevant Data	454
4.1 Absorption, distribution, metabolism and excretion	454
4.2 Genetic and related effects.....	455
4.3 Mechanistic data.....	456
4.4 Mechanisms of carcinogenesis	456
5. Summary of Data Reported.....	456
6. Evaluation	457
References	457

INTRODUCTION TO THE MONOGRAPHS ON BROMOCHLOROACETIC ACID, DIBROMOACETIC ACID AND DIBROMOACETONITRILE	461
Cancer in Humans	462
1. Cohort studies	462
2. Case-control studies	475
3. Meta-analyses and pooled analyses	491
References	491
BROMOCHLOROACETIC ACID	495
1. Exposure Data	495
1.1 Chemical and physical data	495
1.2 Production and use	496
1.3 Occurrence and exposure	496
1.4 Regulations and guidelines	501
2. Cancer in Humans	501
3. Cancer in Experimental Animals	501
3.1 Oral administration	501
4. Other Relevant Data	504
4.1 Absorption, distribution, metabolism and excretion	504
4.2 Genetic and related effects	506
4.3 Mechanistic data	506
4.4 Susceptibility	506
4.5 Mechanisms of carcinogenesis	506
5. Summary of Data Reported	508
6. Evaluation	509
References	509
DIBROMOACETIC ACID	513
1. Exposure Data	513
1.1 Chemical and physical data	513
1.2 Production and use	514
1.3 Occurrence	514
1.4 Regulations and guidelines	519
2. Cancer in Humans	519
3. Cancer in Experimental Animals	519
3.1 Oral administration	519
4. Other Relevant Data	521
4.1 Absorption, distribution, metabolism and excretion	521
4.2 Genetic and related effects	523
4.3 Mechanistic data	527
4.4 Susceptibility	527
4.5 Mechanisms of carcinogenesis	527
5. Summary of Data Reported	528
6. Evaluation	529
References	529

DIBROMOACETONITRILE.....	533
1. Exposure Data	533
1.1 Chemical and physical data	533
1.2 Production and use.....	534
1.3 Occurrence and exposure	534
1.4 Regulations and guidelines	538
2. Cancer in Humans.....	538
3. Cancer in Experimental Animals	538
3.1 Oral administration.....	538
3.2 Skin application.....	541
3.3 Co-exposure with modifying agents.....	541
4. Other Relevant Data	541
4.1 Absorption, distribution, metabolism and excretion	541
4.2 Genetic and related effects.....	544
4.3 Mechanistic data.....	544
4.4 Susceptibility.....	546
4.5 Mechanisms of carcinogenesis	546
5. Summary of Data Reported.....	546
6. Evaluation	547
References	547
LIST OF ABBREVIATIONS.....	551
CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS.....	555

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.

